The DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index.
The Effects of Insulin-Like Growth Factors on Tumorigenesis and Neoplastic Growth
Abstract
Several decades of basic and clinical research have demonstrated that there is an association between the insulin-like growth factors (IGFs) and neoplasia. We begin with a brief discussion of the function and regulation of expression of the IGFs, their receptors and the IGF-binding proteins (IGFBPs). A number of investigational interventional strategies targeting the GH or IGFs are then reviewed. Finally, we have assembled the available scientific knowledge about this relationship for each of the major tumor types. The tumors have been grouped together by organ system and for each of the major tumors, various key elements of the relationship between IGFs and tumor growth are discussed. Specifically these include the presence or absence of autocrine IGF-I and IGF-II production; presence or absence of IGF-I and IGF-II receptor expression; the expression and functions of the IGFBPs; in vitro and in vivo experiments involving therapeutic interventions; and available results from clinical trials evaluating the effect of GH/IGF axis down-regulation in various malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Insulin-Like Growth Factors and Their Binding Proteins: Biological Actions*
JONES, J. I., & CLEMMONS, D. R. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-1-3 · Cited by 4,710
Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study
Chan, J. M., Stampfer, M. J., Giovannucci, E., Gann, P. H., Ma, J., Wilkinson, P., Hennekens, C. H., & Pollak, M. (1998) · Science · doi:10.1126/science.279.5350.563 · Cited by 1,996
Circulating concentrations of insulin-like growth factor I and risk of breast cancer
Hankinson, S. E., Willett, W. C., Colditz, G. A., Hunter, D. J., Michaud, D. S., Deroo, B., Rosner, B., Speizer, F. E., & Pollak, M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)10384-1 · Cited by 1,823
Normal growth and development in the absence of hepatic insulin-like growth factor I
Yakar, S., Liu, J.-L., Stannard, B., Butler, A., Accili, D., Sauer, B., & LeRoith, D. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.13.7324 · Cited by 1,420
Ma, J., Pollak, M. N., Giovannucci, E., Chan, J. M., Tao, Y., Hennekens, C. H., & Stampfer, M. J. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.7.620 · Cited by 1,119
The Insulin-Like Growth Factor-Binding Protein (IGFBP) Superfamily*
Hwa, V., Oh, Y., & Rosenfeld, R. G. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0382 · Cited by 1,079
Lamberts, S. W. J., van der Lely, A.-J., de Herder, W. W., & Hofland, L. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601253340408 · Cited by 1,001
Le Roith, D. (1997) · New England Journal of Medicine · doi:10.1056/nejm199702273360907 · Cited by 897
Insulin-Like Growth Factor 1 and Prostate Cancer Risk: A Population-Based, Case-Control Study
Wolk, A., Mantzoros, C. S., Andersson, S.-O., Bergstrom, R., Signorello, L. B., Lagiou, P., Adami, H.-O., & Trichopoulos, D. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.12.911 · Cited by 575
Sell, C., Rubini, M., Rubin, R., Liu, J. P., Efstratiadis, A., & Baserga, R. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.23.11217 · Cited by 553
Research works printed but not linked: 120
- O’Gorman, 1999, Decreased insulin-like growth factor-II/mannose-6-phosphate receptor expression enhances tumorigenicity in JEG-3 cells., Cancer Res, 59, 5692
- Hofbauer, 1995, Insulin-like growth factor I messenger ribonucleic acid expression in porcine thyroid follicles is regulated by thyrotropin and iodine., Eur J Endocrinol, 132, 605, 10.1530/eje.0.1320605 · doi:10.1530/eje.0.1320605
- Kim, 1998, Frequent loss of imprinting of the H19 and IGF-II genes in ovarian tumors., Am J Med Genet, 80, 391, 10.1002/(SICI)1096-8628(19981204)80:4<391::AID-AJMG16>3.0.CO;2-H · doi:10.1002/(sici)1096-8628(19981204)80:4<391::aid-ajmg16>3.0.co;2-h
- Nonomura, 1997, Altered imprinting of the H19 and insulin-like growth factor II genes in testicular tumors., J Urol, 157, 1977, 10.1016/S0022-5347(01)64913-9 · doi:10.1016/s0022-5347(01)64913-9
- Wu, 1997, Loss of imprinting and overexpression of IGF2 gene in gastric adenocarcinoma., Cancer Lett, 120, 9, 10.1016/S0304-3835(97)00279-6 · doi:10.1016/s0304-3835(97)00279-6
- Werner, 1993, The regulation of insulin-like growth factor-I receptor gene expression by positive and negative zinc-finger transcription factors., Adv Exp Med Biol, 343, 91, 10.1007/978-1-4615-2988-0_10 · doi:10.1007/978-1-4615-2988-0_10
- Okamoto, 1990, Insulin-like growth factor-II/mannose-6-phosphate receptor is incapable of activating GTP-binding proteins in response to mannose-6-phosphate, but capable in response to insulin-like growth factor-II., Biochem Biophys Res Commun, 168, 1201, 10.1016/0006-291X(90)91156-M · doi:10.1016/0006-291x(90)91156-m
- Varga, 1999, Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities., Proc Natl Acad Sci USA, 96, 692, 10.1073/pnas.96.2.692 · doi:10.1073/pnas.96.2.692
- Csernus, 1999, Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro., Proc Natl Acad Sci USA, 96, 3098, 10.1073/pnas.96.6.3098 · doi:10.1073/pnas.96.6.3098
- Pollak, 1998, Mechanism of antineoplastic action of somatostatin analogs., Proc Soc Exp Biol Med, 217, 143, 10.3181/00379727-217-44216 · doi:10.3181/00379727-217-44216
- Antoniades, 1992, Expression of insulin-like growth factors-I and II and their receptor mRNAs in primary human astrocytomas and meningiomas: in vivo studies using in situ hybridization and immunocytochemistry., Int J Cancer, 50, 215, 10.1002/ijc.2910500210 · doi:10.1002/ijc.2910500210
- Sandberg-Nordqvist, 1993, Characterization of insulin-like growth factor-I in human primary brain tumors., Cancer Res, 53, 2475
- Hirano, 1999, Insulin-like growth factor-I content and pattern of expression correlates with histopathologic grade in diffusely infiltrating astrocytomas, Neurooncology, 1, 109
- Lichtor, 1993, Expression of insulin-like growth factors and their receptors in human meningiomas., J Neurooncol, 17, 183, 10.1007/BF01049974 · doi:10.1007/bf01049974
- Hultberg, 1993, Gene expression of insulin-like growth factor-II in human intracranial meningioma., Cancer, 72, 3282, 10.1002/1097-0142(19931201)72:11<3282::AID-CNCR2820721125>3.0.CO;2-N · doi:10.1002/1097-0142(19931201)72:11<3282::aid-cncr2820721125>3.0.co;2-n
- Sara, 1986, Enhancement of insulin-like growth factor-II receptors in glioblastomas., Cancer Lett, 32, 229, 10.1016/0304-3835(86)90174-6 · doi:10.1016/0304-3835(86)90174-6
- Gammeltoft, 1988, Expression of two types of receptors for insulin-like growth factors in human glioma., Cancer Res, 48, 1233
- Glick, 1989, Insulin and insulin-like growth factor-I in brain tumors: binding and in vitro effects., Neurosurgery, 24, 791, 10.1227/00006123-198906000-00001 · doi:10.1227/00006123-198906000-00001
- Burgaud, 1995, Mutant IGF-I receptors as dominant negatives for growth and transformation., Biochem Biophys Res Commun, 214, 475, 10.1006/bbrc.1995.2311 · doi:10.1006/bbrc.1995.2311
- Resnicoff, 1996, Inhibition of rat C6 glioblastoma tumor growth by expression of insulin-like growth factor-I receptor antisense mRNA., Cancer Immunol Immunother, 42, 64, 10.1007/s002620050252 · doi:10.1007/s002620050252
- D’Ambrosio, 1996, A soluble insulin-like growth factor-I receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis., Cancer Res, 56, 4013
- Resnicoff, 1994, Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-I (IGF-I) receptor are nontumorigenic and induce regression of wild-type tumors., Cancer Res, 54, 2218
- Lichtor, 1991, Differential expression of insulin-like growth factor-II in human meningiomas., Neurosurgery, 29, 405, 10.1227/00006123-199109000-00011 · doi:10.1227/00006123-199109000-00011
- Sandberg-Nordqvist, 1997, A high ratio of insulin-like growth factor-II/IGFBP-2 mRNA as a marker for anaplasia in meningiomas., Cancer Res, 57, 2611
- Kurihara, 1989, Characterization of insulin-like growth factor-I and epidermal growth factor receptors in meningioma., J Neurosurg, 71, 538, 10.3171/jns.1989.71.4.0538 · doi:10.3171/jns.1989.71.4.0538
- Tsutsumi, 1994, Effect of suramin on 125I-IGF-I binding to human meningiomas and on proliferation of meningioma cells., J Neurosurg, 80, 502, 10.3171/jns.1994.80.3.0502 · doi:10.3171/jns.1994.80.3.0502
- Friend, 1999, Growth hormone receptor expression and function in meningioma: effect of a specific receptor antagonist., J Neurosurg, 91, 93, 10.3171/jns.1999.91.1.0093 · doi:10.3171/jns.1999.91.1.0093
- McCutcheon, J Neurosurg, 92, 306, 10.3171/jns.2000.92.2.0306 · doi:10.3171/jns.2000.92.2.0306
- Tricoli, 1986, Enhanced levels of insulin-like growth factor messenger RNA in human colon carcinomas and liposarcomas., Cancer Res, 46, 6169
- Culouscou, 1987, Simultaneous production of insulin-like growth factor-I and epidermal growth factor competing growth factors by HT-29 human colon cancer line., Int J Cancer, 40, 646, 10.1002/ijc.2910400513 · doi:10.1002/ijc.2910400513
- Lambert, 1990, Abnormal expression and structural modification of the of insulin-like growth factor-II gene in human colorectal tumors., Int J Cancer, 46, 405, 10.1002/ijc.2910460313 · doi:10.1002/ijc.2910460313
- Zarrilli, 1994, Expression of insulin-like growth factor-II and IGF-I receptor during proliferation and differentiation of CaCo-2 human colon carcinoma cells., Cell Growth Diff, 5, 1085
- Guo, 1995, Insulin-like growth factor-II expression in carcinoma in colon cell lines: implications for autocrine actions., J Am Coll Surg, 181, 145
- Kawamoto, 1998, Expression of insulin-like growth factor-II can predict the prognosis of human colorectal cancer patients: correlation with tumor progression, proliferative activity and survival., Oncology, 55, 242, 10.1159/000011858 · doi:10.1159/000011858
- Kawamoto, 1999, Possible paracrine mechanism of insulin-like growth factor-2 in the development of liver metastasis from colorectal carcinoma., Cancer, 85, 18, 10.1002/(SICI)1097-0142(19990101)85:1<18::AID-CNCR3>3.0.CO;2-4 · doi:10.1002/(sici)1097-0142(19990101)85:1<18::aid-cncr3>3.0.co;2-4
- Rouyer-Fessard, 1990, Expression of two types of receptor for insulin-like growth factors in human colonic epithelium., Gastroenterology, 98, 703, 10.1016/0016-5085(90)90291-8 · doi:10.1016/0016-5085(90)90291-8
- Adenis, 1995, Type I insulin-like growth factor receptors in human colorectal cancer, Eur J Cancer, 31A, 50, 10.1016/0959-8049(94)00368-F · doi:10.1016/0959-8049(94)00368-f
- Singh, 1994, Episomal expression of sense and antisense insulin-like growth factor (IGF) binding protein-4 complimentary DNA alters the mitogenic response of a human colon cancer cell line (HT-29) by mechanisms that are independent of and dependent upon IGF-I., Cancer Res, 54, 6563
- Macdonald, 1999, Growth inhibition and differentiation of the human colon carcinoma cell line, Caco-2, by constitutive expression of insulin-like growth factor binding protein-3., J Gastroenterol Hepatol, 14, 72, 10.1046/j.1440-1746.1999.01803.x · doi:10.1046/j.1440-1746.1999.01803.x
- Qin, 1991, Somatostatin analogue RC-160 inhibits the growth of transplanted colon cancer in rats., Int J Cancer, 47, 765, 10.1002/ijc.2910470524 · doi:10.1002/ijc.2910470524
- Alonso, 1992, Effects of pentagastrin and of the somatostatin analogue (SMS 201–995) on growth of CT26 in vivo adenocarcinoma of the colon., Surg Gynecol Obstet, 175, 441
- Qin, 1992, Treatment of liver metastasis of human colon cancers in nude mice with somatostatin analogue RC-160., Int J Cancer, 52, 791, 10.1002/ijc.2910520520 · doi:10.1002/ijc.2910520520
- Glass, 1994, Serum concentrations of insulin-like growth factor-I in colonic neoplasia., Acta Oncol, 33, 70, 10.3109/02841869409098380 · doi:10.3109/02841869409098380
- Iftikhar, 1991, The effect of long-acting somatostatin analogue SMS 201–995 therapy on tumor kinetic measurements and serum tumor marker concentrations in primary rectal cancer., Br J Cancer, 63, 971, 10.1038/bjc.1991.212 · doi:10.1038/bjc.1991.212
- Cascinu, 1995, A randomized trial of octreotide vs. best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy., Br J Cancer, 71, 97, 10.1038/bjc.1995.19 · doi:10.1038/bjc.1995.19
- Goldberg, 1995, A phase III evaluation of a somatostatin analogue (octreotide) in the treatment of patients with asymptomatic advanced colon carcinoma., Cancer, 76, 961, 10.1002/1097-0142(19950915)76:6<961::AID-CNCR2820760608>3.0.CO;2-A · doi:10.1002/1097-0142(19950915)76:6<961::aid-cncr2820760608>3.0.co;2-a
- Cascinu, 1997, Inhibition of tumor cell kinetics and serum insulin-like growth factor-I levels by octreotide in colorectal cancer patients., Gastroenterology, 113, 767, 10.1016/S0016-5085(97)70170-7 · doi:10.1016/s0016-5085(97)70170-7
- Guo, 1993, Insulin-like growth factor binding protein modulates the growth response to insulin-like growth factor-I by human gastric cancer cells., Gastroenterology, 104, 1595, 10.1016/0016-5085(93)90634-O · doi:10.1016/0016-5085(93)90634-o
- Ohmura, 1990, Insulin-like growth factor-I and transforming growth factor α as autocrine growth factors in human pancreatic cancer cell growth., Cancer Res, 50, 103
- Oku, 1991, Effects of various growth factors on growth of a cloned human esophageal squamous cancer cell line in a protein-free medium., Anticancer Res, 11, 1591
- Chen, 1991, Overexpression of epidermal growth factor and insulin-like growth factor-I receptors and autocrine stimulation in human esophageal carcinoma cells., Cancer Res, 51, 1898
- D’Errico, 1994, Expression of insulin-like growth factor-II in human hepatocellular carcinomas: an immunohistochemical study., Path Intl, 44, 131, 10.1111/j.1440-1827.1994.tb01697.x · doi:10.1111/j.1440-1827.1994.tb01697.x
- Sohda, 1997, Co-localization of insulin-like growth factor-II and the proliferation marker MIB1 in hepatocellular carcinoma cells., J Clin Pathol, 50, 135, 10.1136/jcp.50.2.135 · doi:10.1136/jcp.50.2.135
- Minuto, 1986, Evidence for an increased somatomedin-C/insulin-like growth factor-I content in primary human lung tumors., Cancer Res, 46, 985
- Minuto, 1988, Evidence for autocrine mitogenic stimulation by somatomedin-C/insulin-like growth factor-I on an established human lung cancer cell line., Cancer Res, 46, 3716
- Jaques, 1988, Production of immunoreactive insulin-like growth factor-I and response to exogenous IGF-I in small cell lung cancer cell lines., Exp Cell Res, 176, 336, 10.1016/0014-4827(88)90335-7 · doi:10.1016/0014-4827(88)90335-7
- Macaulay, 1990, Autocrine function for insulin-like growth factor-I in human small cell lung cancer cell lines and fresh tumor cells., Cancer Res, 50, 2511
- Reeve, 1990, Production of immunoreactive insulin-like growth factor (IGF)-I and IGF binding proteins by human lung tumors., Br J Cancer, 61, 727, 10.1038/bjc.1990.163 · doi:10.1038/bjc.1990.163
- Schardt, 1993, Characterization of insulin-like growth factor-II receptors in human small cell lung cancer cell lines., Exp Cell Res, 204, 22, 10.1006/excr.1993.1004 · doi:10.1006/excr.1993.1004
- Zia, 1996, Monoclonal antibody αIR3 inhibits non-small cell lung cancer growth in vitro and in vivo., J Cell Biochem Suppl, 24, 269, 10.1002/jcb.240630522 · doi:10.1002/jcb.240630522
- Lee, 1996, Antitumor effects of an adenovirus expressing antisense insulin-like growth factor-I receptor on human lung cancer cell lines., Cancer Res, 56, 3038
- Long, 1998, Enhanced invasion and liver colonization by lung carcinoma cells overexpressing the type I IGF receptor., Exp Cell Res, 238, 116, 10.1006/excr.1997.3814 · doi:10.1006/excr.1997.3814
- Taylor, 1988, In vitro and in vivo inhibition of human small cell lung carcinoma (NCI-H69) growth by a somatostatin analogue., Biochem Biophys Res Commun, 153, 81, 10.1016/S0006-291X(88)81192-6 · doi:10.1016/s0006-291x(88)81192-6
- Bogden, 1990, Response of human lung tumor xenografts with a somatostatin analogue (Somatuline)., Cancer Res, 50, 4360
- Pinski, 1994, Effects of somatostatin analog RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice., Br J Cancer, 70, 886, 10.1038/bjc.1994.415 · doi:10.1038/bjc.1994.415
- Macaulay, 1991, Experimental and clinical studies with somatostatin analogue octreotide in small cell lung cancer., Br J Cancer, 64, 451, 10.1038/bjc.1991.330 · doi:10.1038/bjc.1991.330
- Cotto, 1994, Phase I study of the somatostatin analogue somatuline in refractory small-cell lung carcinoma., Ann Oncol, 5, 290, 10.1093/oxfordjournals.annonc.a058812 · doi:10.1093/oxfordjournals.annonc.a058812
- Marschke Jr, 1999, Phase II study of high dose somatostatin analogue in patients either previously treated or untreated who have extensive-stage small cell lung cancer., Am J Clin Oncol, 22, 15, 10.1097/00000421-199902000-00004 · doi:10.1097/00000421-199902000-00004
- Minuto, 1989, Immunoreactive insulin-like growth factor (IGF)-I and IGF binding protein content in human thyroid tissue., J Clin Endocrinol Metab, 68, 621, 10.1210/jcem-68-3-621 · doi:10.1210/jcem-68-3-621
- Onoda, 1992, Autocrine role of insulin-like growth factor-I in a human thyroid cancer cell line, Eur J Cancer, 28A, 1904, 10.1016/0959-8049(92)90033-X · doi:10.1016/0959-8049(92)90033-x
- Yashiro, 1989, Expression of insulin-like growth factor receptors in primary human thyroid neoplasms., Acta Endocrinol (Copenh), 121, 112, 10.1530/acta.0.1210112 · doi:10.1530/acta.0.1210112
- Gebauer, 1998, mRNA expression of the components of the insulin-like growth factor system in breast cancer cell lines, tissues and metastatic breast cancer cells., Anticancer Res, 18, 1191
- De Leon, 1988, Demonstration of insulin-like growth factor (IGF)-I and IGF-II receptors and binding protein in human breast cancer cell lines., Biochem Biophys Res Commun, 152, 398, 10.1016/S0006-291X(88)80727-7 · doi:10.1016/s0006-291x(88)80727-7
- Clemmons, 1990, Insulin-like growth factor binding protein secretion by breast carcinoma cell lines: correlation with estrogen receptor status., Endocrinology, 127, 2679, 10.1210/endo-127-6-2679 · doi:10.1210/endo-127-6-2679
- Pratt, 1994, Insulin-like growth factor binding protein-3 (IGFBP-3) inhibits estrogen-stimulated breast cancer cell proliferation., Biochem Biomed Res Commun, 198, 292, 10.1006/bbrc.1994.1041 · doi:10.1006/bbrc.1994.1041
- Nickerson, 1997, Insulin-like growth factor binding protein-3 induces apoptosis in MCF-7 breast cancer cells., Biochem Biomed Res Commun, 237, 690, 10.1006/bbrc.1997.7089 · doi:10.1006/bbrc.1997.7089
- Martin, 1995, Insulin-like growth factor binding protein 3 (IGFBP-3) production by MCF-7 breast cancer cells: stimulation by retinoic acid and cyclic adenosine monophosphate and differential effects of estradiol., Endocrinology, 136, 1219, 10.1210/endo.136.3.7532580 · doi:10.1210/endo.136.3.7532580
- Van den Berg, 1997, Polyethylene glycol conjugated insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice., Eur J Cancer, 33, 1108, 10.1016/S0959-8049(97)00071-3 · doi:10.1016/s0959-8049(97)00071-3
- Rohlik, 1987, An antibody to the receptor for insulin-like growth factor receptor-I inhibits the growth of MCF-7 cells in tissue culture., Biochem Biophys Res Commun, 149, 276, 10.1016/0006-291X(87)91635-4 · doi:10.1016/0006-291x(87)91635-4
- De Leon, 1992, Effects of insulin-like growth factors (IGFs) and IGF receptor antibodies on the proliferation of human breast cancer cells., Growth Factors, 6, 327, 10.3109/08977199209021544 · doi:10.3109/08977199209021544
- Vennin, 1989, Effect of the long acting somatostatin analogue SMS 201–995 (Sandostatin) in advanced breast cancer., Anticancer Res, 9, 153
- Di Leo, 1995, Biological and clinical evaluation of lanreotide (BIM 23014), a somatostatin analogue in the treatment of advanced breast cancer., Breast Cancer Res Treat, 34, 237, 10.1007/BF00689715 · doi:10.1007/bf00689715
- Canobbio, 1995, Somatuline (BIM 23014) and tamoxifen treatment of postmenopausal breast cancer patients: clinical activity and effect on insulin-like growth factor-I levels., Anticancer Res, 15, 2687
- O’Byrne, 1999, Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer., Br J Cancer, 79, 1413, 10.1038/sj.bjc.6690226 · doi:10.1038/sj.bjc.6690226
- Ingle, 1999, A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma., Cancer, 85, 1284, 10.1002/(SICI)1097-0142(19990315)85:6<1284::AID-CNCR10>3.0.CO;2-P · DOI
- Yee, 1991, Expression of insulin-like growth factor-I, its binding proteins, and its receptors in ovarian cancer., Cancer Res, 51, 5107
- Resnicoff, 1993, Insulin-like growth factor-I and its receptor mediate the autocrine proliferation of human ovarian carcinoma cell lines., Lab Invest, 69, 756
- Krywicki, 1993, Regulation of insulin-like growth factor binding proteins in ovarian cancer cells by oestrogen, Eur J Cancer, 29A, 2015, 10.1016/0959-8049(93)90464-Q · doi:10.1016/0959-8049(93)90464-q
- Kanety, 1996, Increased insulin-like growth factor binding protein 2 (IGFBP-2) gene expression and protein production lead to high IGFBP-2 content in malignant ovarian cyst fluid., Br J Cancer, 73, 1069, 10.1038/bjc.1996.206 · doi:10.1038/bjc.1996.206
- Muller, 1998, Antisense phophorothioate oligodeoxynucleotide down-regulation of the insulin-like growth factor-I receptor in ovarian cancer cells., Int J Cancer, 77, 567, 10.1002/(SICI)1097-0215(19980812)77:4<567::AID-IJC16>3.0.CO;2-3 · doi:10.1002/(sici)1097-0215(19980812)77:4<567::aid-ijc16>3.0.co;2-3
- Klienman, 1993, Regulation of endometrial cancer cell growth by insulin-like growth factors and the leutinizing hormone-releasing hormone antagonist SB-75., Regul Pept, 48, 91, 10.1016/0167-0115(93)90338-9 · doi:10.1016/0167-0115(93)90338-9
- Hana, 1994, Expression of insulin-like growth factors and their binding proteins in the estrogen responsive Ishikawa human endometrial cancer cell line., Endocrinology, 135, 2511, 10.1210/endo.135.6.7527333 · doi:10.1210/endo.135.6.7527333
- Elkas, 1998, The effects of tamoxifen on endometrial insulin-like growth factor-I expression., Obstet Gynecol, 91, 45, 10.1016/S0029-7844(97)00549-8 · doi:10.1016/s0029-7844(97)00549-8
- Talavera, 1990, Insulin-like growth factor-I receptors in normal and neoplastic human endometrium., Cancer Res, 50, 3019
- Kleinman, 1995, Modulation of insulin-like growth factor-I (IGF-I) receptors and membrane associated IGF-binding proteins in endometrial cancer cells by estradiol., Endocrinology, 136, 2531, 10.1210/endo.136.6.7750475 · doi:10.1210/endo.136.6.7750475
- Pearl, 1993, Mitogenic activity of growth factors in the human endometrial adenocarcinoma cell lines HEC-1-A and KLE., Gynecol Oncol, 49, 325, 10.1006/gyno.1993.1134 · doi:10.1006/gyno.1993.1134
- Steller, 1996, Overexpression of insulin-like growth factor-I receptor and autocrine stimulation in human cervical cancer cells., Cancer Res, 56, 1761
- Kaicer, 1991, Insulin-like growth factor-I and IGFBPs: stimulatory and inhibitory factors secreted by human prostate adenocarcinoma cells., Growth Factors, 4, 231, 10.3109/08977199109104819 · doi:10.3109/08977199109104819
- Connolly, 1994, Regulation of DU 145 human prostate cancer cell proliferation by insulin-like growth factors and its interaction with the epidermal growth factor autocrine loop., Prostate, 24, 167, 10.1002/pros.2990240402 · doi:10.1002/pros.2990240402
- Lamharzi, 1998, Growth hormone-releasing hormone antagonist MZ-5–156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor-II in tumors., Proc Natl Acad Sci USA, 95, 8864, 10.1073/pnas.95.15.8864 · doi:10.1073/pnas.95.15.8864
- Figueroa, 1995, Proliferation of cultured human prostate cancer cells is inhibited by insulin-like growth factor (IGF) binding protein-1: evidence for an IGF-II autocrine growth loop., J Clin Endocrinol Metab, 80, 3476, 10.1210/jcem.80.12.8530586 · doi:10.1210/jcem.80.12.8530586
- Schally, 1987, Somatostatin analogs as adjuncts to agonists of leutinizing hormone-releasing hormone in the treatment of experimental prostate cancer., Proc Natl Acad Sci USA, 84, 7275, 10.1073/pnas.84.20.7275 · doi:10.1073/pnas.84.20.7275
- Pinski, 1993, Effect of somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 on growth of PC-3 human prostate cancer xenografts in nude mice., Int J Cancer, 55, 963, 10.1002/ijc.2910550615 · doi:10.1002/ijc.2910550615
- Pinski, 1993, Somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 inhibit the growth of androgen-independent DU-145 human prostate cancer line in nude mice., Cancer Lett, 71, 189, 10.1016/0304-3835(93)90115-P · doi:10.1016/0304-3835(93)90115-p
- Jungwirth, 1997, Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone., Br J Cancer, 75, 1585, 10.1038/bjc.1997.271 · doi:10.1038/bjc.1997.271
- Parmar, 1992, Therapeutic response to somatostatin analogue BIM 23014 in metastatic prostate cancer., Clin Exp Metastasis, 10, 3, 10.1007/BF00163570 · doi:10.1007/bf00163570
- Figg, 1995, A phase I study of the somatostatin analogue somatuline in patients with metatstatic hormone-refractory prostate cancer., Cancer, 75, 2159, 10.1002/1097-0142(19950415)75:8<2159::AID-CNCR2820750820>3.0.CO;2-O · doi:10.1002/1097-0142(19950415)75:8<2159::aid-cncr2820750820>3.0.co;2-o
- Maulard, 1995, Phase I-II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer., Cancer Chemother Pharmacol, 36, 259, 10.1007/BF00685857 · doi:10.1007/bf00685857
- Weima, 1989, Human teratocarcinoma cells express functional insulin-like growth factor-I receptors., Exp Cell Res, 184, 427, 10.1016/0014-4827(89)90341-8 · doi:10.1016/0014-4827(89)90341-8
- Jungwirth, 1997, Growth hormone-releasing hormone antagonist MZ-4–71 inhibits in vivo proliferation of Caki-I renal adenocarcinoma., Proc Natl Acad Sci USA, 94, 5810, 10.1073/pnas.94.11.5810 · DOI
- Pinski, 1996, Somatostatin analog RC-160 inhibits the growth of human osteosarcomas in nude mice., Int J Cancer, 65, 870, 10.1002/(SICI)1097-0215(19960315)65:6<870::AID-IJC27>3.0.CO;2-6 · doi:10.1002/(sici)1097-0215(19960315)65:6<870::aid-ijc27>3.0.co;2-6
- Foley Jr, 1982, Demonstration of receptors for insulin and insulin-like growth factors on Swarm rat chondrosarcoma chondrocytes., J Biol Chem, 25, 663, 10.1016/S0021-9258(19)68244-X · doi:10.1016/s0021-9258(19)68244-x
- Seong, 1994, Insulin-like growth factor-I regulation of Swarm rat chondrosarcoma chondrocytes in culture., Exp Cell Res, 211, 238, 10.1006/excr.1994.1083 · doi:10.1006/excr.1994.1083
- Neely, 1991, Insulin-like growth factors are mitogenic for human keratinocytes and a squamous cell carcinoma, J Invest Dermatol, 96, 104, 10.1111/1523-1747.ep12515914 · doi:10.1111/1523-1747.ep12515914
- Wilker, 1999, Enhancement of susceptibility to diverse skin tumor promoters by activation of insulin-like growth factor-I receptor in the epidermis of transgenic mice., Mol Carcinog, 25, 122, 10.1002/(SICI)1098-2744(199906)25:2<122::AID-MC7>3.0.CO;2-8 · doi:10.1002/(sici)1098-2744(199906)25:2<122::aid-mc7>3.0.co;2-8
- Vetter, 1986, Human leukemic cells: receptor binding and biological effects of insulin and insulin-like growth factors., Leukemia Res, 10, 1201, 10.1016/0145-2126(86)90238-9 · doi:10.1016/0145-2126(86)90238-9
- Pepe, 1987, Receptor binding and mitogenic effects of insulin and insulin-like growth factor-I and II for human myeloid leukemic cells., J Cell Physiol, 133, 219, 10.1002/jcp.1041330204 · DOI
- Sinclair, 1988, Effects of insulin and insulin-like growth factor-I on growth of human leukemia cells in serum-free and protein-free medium., Blood, 72, 66, 10.1182/blood.V72.1.66.66 · doi:10.1182/blood.v72.1.66.66
- Estrov, 1991, Human growth hormone and insulin-like growth factor-I enhance the proliferation of human leukemic blasts., J Clin Oncol, 9, 394, 10.1200/JCO.1991.9.3.394 · doi:10.1200/jco.1991.9.3.394
- Conlon, 1995, Long R-3 insulin-like growth factor-I (IGF-I) stimulates organ growth but reduces plasma IGF-I, IGF-II and IGF binding protein concentration in guinea pigs., J Endocrinol, 146, 247, 10.1677/joe.0.1460247 · doi:10.1677/joe.0.1460247
Cited by
Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms
Calle, E. E., & Kaaks, R. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1408 · Cited by 3,613
Androgen Receptor in Prostate Cancer
Heinlein, C. A., & Chang, C. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0032 · Cited by 1,780
Renehan, A. G., Zwahlen, M., Minder, C., O'Dwyer, S. T., Shalet, S. M., & Egger, M. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16044-3 · Cited by 1,697
Insulin-like growth factors and neoplasia
Pollak, M. N., Schernhammer, E. S., & Hankinson, S. E. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1387 · Cited by 1,463
Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management
Colao, A., Ferone, D., Marzullo, P., & Lombardi, G. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0022 · Cited by 1,309
The insulin-like growth factor system and cancer
LeRoith, D., & Roberts, C. T. (2003) · Cancer Letters · doi:10.1016/s0304-3835(03)00159-9 · Cited by 1,124
Fasting Serum Glucose Level and Cancer Risk in Korean Men and Women
Jee, S. H. (2005) · JAMA · doi:10.1001/jama.293.2.194 · Cited by 988
Overweight, obesity, and cancer risk
Bianchini, F., Kaaks, R., & Vainio, H. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00849-5 · Cited by 929
Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)
Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D., & Pollak, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1852 · Cited by 882
The IGF‐1 receptor in cancer biology
Baserga, R., Peruzzi, F., & Reiss, K. (2003) · International Journal of Cancer · doi:10.1002/ijc.11487 · Cited by 642
Structural biology of insulin and IGF1 receptors: implications for drug design
De Meyts, P., & Whittaker, J. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd917 · Cited by 582
Garcı́a-Echeverrı́a, C., Pearson, M. A., Marti, A., Meyer, T., Mestan, J., Zimmermann, J., Gao, J., Brueggen, J., Capraro, H.-G., Cozens, R., et al. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00051-0 · Cited by 542
Insulin-like growth factors and cancer
Fürstenberger, G., & Senn, H.-J. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00731-3 · Cited by 536
Ferretti, C., Bruni, L., Dangles-Marie, V., Pecking, A. P., & Bellet, D. (2006) · Human Reproduction Update · doi:10.1093/humupd/dml048 · Cited by 509
Sandhu, M. S. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.13.972 · Cited by 496
Obesity and cancer risk: the role of the insulin-IGF axis
Renehan, A. G., Frystyk, J., & Flyvbjerg, A. (2006) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2006.08.006 · Cited by 480
Self-citationMolecular interactions of the IGF system
Denley, A., Cosgrove, L. J., Booker, G. W., Wallace, J. C., & Forbes, B. E. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.04.004 · Cited by 437
The role of insulin receptors and IGF-I receptors in cancer and other diseases
Frasca, F., Pandini, G., Sciacca, L., Pezzino, V., Squatrito, S., Belfiore, A., & Vigneri, R. (2008) · Archives of Physiology and Biochemistry · doi:10.1080/13813450801969715 · Cited by 410
Insulin Receptor Isoforms in Physiology and Disease: An Updated View
Belfiore, A., Malaguarnera, R., Vella, V., Lawrence, M. C., Sciacca, L., Frasca, F., Morrione, A., & Vigneri, R. (2017) · Endocrine Reviews · doi:10.1210/er.2017-00073 · Cited by 375
Ou-Yang, S.-S., Lu, J.-Y., Kong, X.-Q., Liang, Z.-J., Luo, C., & Jiang, H. (2012) · Acta Pharmacologica Sinica · doi:10.1038/aps.2012.109 · Cited by 352
Zheng, X., Baker, H., Hancock, W. S., Fawaz, F., McCaman, M., & Pungor, E. (2006) · Biotechnology Progress · doi:10.1021/bp060121o · Cited by 346
Cancer, Physical Activity, and Exercise
Brown, J. C., Winters‐Stone, K., Lee, A., & Schmitz, K. H. (2012) · Comprehensive Physiology · doi:10.1002/cphy.c120005 · Cited by 346
Association of Obesity and Cancer Risk in Canada
Pan, S. Y. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh041 · Cited by 339
Frystyk, J. (2004) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2004.06.001 · Cited by 338
Metabolic Factors Associated with Benign Prostatic Hyperplasia
Parsons, J. K., Carter, H. B., Partin, A. W., Windham, B. G., Metter, E. J., Ferrucci, L., Landis, P., & Platz, E. A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2799 · Cited by 336
Endogenous Hormones and Ovarian Cancer: Epidemiology and Current Hypotheses
Lukanova, A., & Kaaks, R. (2005) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.98.14.1 · Cited by 314
Sklar, C. A. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.7.3136 · Cited by 310
IGF1R signalling and its inhibition
Riedemann, J., & Macaulay, V. M. (2006) · Endocrine-Related Cancer · doi:10.1677/erc.1.01280 · Cited by 301
Epidemiology of testicular cancer: An overview
Garner, M. J., Turner, M. C., Ghadirian, P., & Krewski, D. (2005) · International Journal of Cancer · doi:10.1002/ijc.21032 · Cited by 276
Growth Hormone Treatment and Risk of Second Neoplasms in the Childhood Cancer Survivor
Ergun-Longmire, B., Mertens, A. C., Mitby, P., Qin, J., Heller, G., Shi, W., Yasui, Y., Robison, L. L., & Sklar, C. A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0656 · Cited by 274
Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria
Rapp, K., Schroeder, J., Klenk, J., Ulmer, H., Concin, H., Diem, G., Oberaigner, W., & Weiland, S. K. (2006) · Diabetologia · doi:10.1007/s00125-006-0207-6 · Cited by 270
Insulin-Like Growth Factor 1 (IGF-1) Signaling in Glucose Metabolism in Colorectal Cancer
Kasprzak, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126434 · Cited by 248
Visceral adiposity, insulin resistance and cancer risk
Donohoe, C. L., Doyle, S. L., & Reynolds, J. V. (2011) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-3-12 · Cited by 247
O’Connor, J. C., McCusker, R. H., Strle, K., Johnson, R. W., Dantzer, R., & Kelley, K. W. (2008) · Cellular Immunology · doi:10.1016/j.cellimm.2007.09.010 · Cited by 238
“Cytokine immunotherapy and IGF-I receptor inhibition are two anti-cancer treatments that have been validated in animal models and are in clinical trials for the treatment of certain types of human cancers [73,74].”
BackgroundUlanet, D. B., Ludwig, D. L., Kahn, C. R., & Hanahan, D. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914076107 · Cited by 235
Non-Islet Cell Tumour-Induced Hypoglycaemia: A Review of the Literature Including Two New Cases
de Groot, J. W. B., Rikhof, B., van Doorn, J., Bilo, H. J. G., Alleman, M. A., Honkoop, A. H., & van der Graaf, W. T. A. (2007) · Endocrine Related Cancer · doi:10.1677/erc-07-0161 · Cited by 222
Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients
Cappuzzo, F., Varella-Garcia, M., Finocchiaro, G., Skokan, M., Gajapathy, S., Carnaghi, C., Rimassa, L., Rossi, E., Ligorio, C., Di Tommaso, L., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604439 · Cited by 178
Insulin-like growth factor (IGF) axis in cancerogenesis
Kasprzak, A., Kwasniewski, W., Adamek, A., & Gozdzicka-Jozefiak, A. (2017) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2016.08.007 · Cited by 130
Kaaks, R., Bellati, C., Venturelli, E., Rinaldi, S., Secreto, G., Biessy, C., Pala, V, Sieri, S., & Berrino, F. (2003) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1601647 · Cited by 120
Targeting of the protein interaction site between FAK and IGF-1R
Zheng, D., Kurenova, E., Ucar, D., Golubovskaya, V., Magis, A., Ostrov, D., Cance, W. G., & Hochwald, S. N. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.07.156 · Cited by 30
van Varsseveld, N. C., van Bunderen, C. C., Franken, A. A. M., Koppeschaar, H. P. F., van der Lely, A. J., & Drent, M. L. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1764 · Cited by 26
Metadata
- Authors
- Khandwala, H. M., McCutcheon, I. E., Flyvbjerg, A., & Friend, K. E.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2000-06-01
- Volume
- 21
- Issue
- 3
- Pages
- 215-244
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2160835537
- Cited by
- 843
- References
- 139
- FWCI
- 26.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.